Frontiers in Cardiovascular Medicine (Mar 2022)

Case Report: Two Case Reports of Acute Myopericarditis After mRNA COVID-19 Vaccine

  • Carlotta Sciaccaluga,
  • Flavio D'Ascenzi,
  • Matteo Cameli,
  • Maddalena Gallotta,
  • Daniele Menci,
  • Giovanni Antonelli,
  • Benedetta Banchi,
  • Veronica Mochi,
  • Serafina Valente,
  • Marta Focardi

DOI
https://doi.org/10.3389/fcvm.2022.827237
Journal volume & issue
Vol. 9

Abstract

Read online

BackgroundCases of myocarditis and myopericarditis after mRNA COVID-19 vaccines have been reported, especially after the second dose and in young males. Their course is generally benign, with symptoms onset after 24–72 h from the dose.Case SummaryWe report two cases of myopericarditis after the second dose of the mRNA-1273 COVID-19 vaccine in two young males. Both the patients were administered the mRNA-1273 COVID-19 vaccine from the same batch on the same day and experienced fever on the same day of the vaccine, and symptoms consisted of myopericarditis 3 days after the dose.DiscussionMyopericarditis is usually considered an uncommon adverse reaction after various vaccinations, reported also after the mRNA COVID-19 vaccine. Several explanations have been proposed, including an abnormal activation of the immune system leading to a pro-inflammatory cascade responsible for myocarditis development. Both patients experienced the same temporal onset as well as the same symptoms, it is also useful to underscore that both vaccines belonged to the same batch of vaccines. However, despite these cases, vaccination against COVID-19 far outweighs the risk linked to COVID-19 infection and remains the best option to overcome this disease.

Keywords